Slingshot members are tracking this event:
New Data for VIBATIV (telavancin) Reported in Presentations at IDWeek 2016
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
|TBPH||Community voting in process|
"Interestingly, our retrospective analytical modeling of data from the ATTAIN studies highlights a specific patient population that not only achieved better clinical outcomes with VIBATIV but also incurred lower overall healthcare costs as compared to vancomycin," said Dr. Bruss. "Additionally, the comparable effect of VIBATIV and vancomycin treatment on patients' renal function highlighted by our second analysis may provide further rationale for additional evaluations of the risk of nephrotoxicity associated with VIBATIV treatment. This builds on and supports similar findings presented earlier this year at ATS 2016 which showed no statistically significant differences in rates of nephrotoxicity for treatment with VIBATIV compared to vancomycin in the ATTAIN trials."
Slingshot Insights Explained
Nov 01, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Vibativ, Telavancin